[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100638873":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":25,"centralContacts":30,"locations":36,"responsibleParty":52,"collaborators":25,"id":54,"slug":55,"hasResults":56,"nctId":57,"briefTitle":58,"officialTitle":59,"acronym":25,"eligibilityCriteria":60,"healthyVolunteers":61,"sex":62,"minAge":63,"maxAge":64,"enrollmentInfo":65,"targetDuration":25,"studyType":68,"phases":69,"briefSummary":71,"conditions":72,"keywords":25,"overallStatus":74,"whyStopped":25,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":84},{"fullName":5,"class":6},"Addpharma Inc.","INDUSTRY",[8,15],{"label":9,"type":10,"description":11,"interventionNames":12},"Sequence A","EXPERIMENTAL","Period 1: Fasted, Period 2: Fed",[13,14],"Drug: AD-230 (Fasted)","Drug: AD-230 (Fed)",{"label":16,"type":10,"description":17,"interventionNames":18},"Sequence B","Period 1: Fed, Period 2: Fasted",[13,14],[20,26],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","AD-230 (Fasted)","AD-230 1Tab., Per Oral, Fasted",[9,16],null,{"type":21,"name":27,"description":28,"armGroupLabels":29,"otherNames":25},"AD-230 (Fed)","AD-230 1 Tab., Per Oral, Fed state",[9,16],[31],{"name":32,"role":33,"phone":34,"phoneExt":25,"email":35},"Sarah Yoon","CONTACT","031-891-5576","sryoon@addpharma.co.kr",[37],{"facility":38,"status":25,"city":39,"state":25,"zip":25,"country":40,"countryCode":25,"cosmosGeoPoint":41,"geoPoint":46,"contacts":47},"Kyungpook National university hospital","Daegu","South Korea",{"type":42,"coordinates":43},"Point",[44,45],128.59111,35.87028,{"lat":45,"lon":44},[48],{"name":49,"role":33,"phone":50,"phoneExt":25,"email":51},"Young-Ran Yoon","+82-53-420-4950","yry@knu.ac.kr",{"type":53,"investigatorFullName":25,"investigatorTitle":25,"investigatorAffiliation":25,"oldNameTitle":25,"oldOrganization":25},"SPONSOR","100638873","phase-1-a-clinical-trial-to-assess-the-pharmacokinetics-safety-and-food-effect-of-ad-230-in-healthy-adults-100638873",false,"NCT07618845","A Clinical Trial to Assess the Pharmacokinetics, Safety, and Food Effect of AD-230 in Healthy Adults","A Randomized, Open-label, 2-period, 2-sequence, Crossover Study to Evaluate the Food Effect on the Safety and the Pharmacokinetics of AD-230 in Healthy Adult Volunteers","Inclusion Criteria:\n\n* Body mass index (BMI) between 18.5 kg\u002Fm2 and 29.9 kg\u002Fm2 at the time of screening visit\n* Subjects aged 19 years or older and under 65 years at the screening visit\n\nExclusion Criteria:\n\n* Participation in another clinical study with an investigational drug within the 6 months from scheduled first administration\n* Other exclusions applied",true,"ALL","19 Years","64 Years",{"count":66,"type":67},24,"ESTIMATED","INTERVENTIONAL",[70],"PHASE1","A clinical trial to assess the pharmacokinetics, safety, and food effect of AD-230 in healthy adults",[73],"Chronic Liver Disease (CLD)","NOT_YET_RECRUITING","2026-05-26",{"date":77,"type":78},"2026-06-01","ACTUAL",{"date":80,"type":67},"2026-05",{"date":82,"type":67},"2026-07",{"name":5,"class":6},1]